Abstract
MicroRNAs (miRNAs) are small conserved noncoding RNAs which function as posttranscriptional regulators of gene expression. Studies over the last 20 years have revealed the essential functions of miRNAs in regulating cardiovascular biology (such as cardiovascular cell differentiation, growth, proliferation and apoptosis) and crucial roles in controlling cardiovascular disease (CVD), indicating the potential of these small molecules as therapeutic targets and/or agents for CVD. Moreover, miRNAs in the circulation or other body fluids are stable and readily detectable, and more importantly often disease-associated, which makes them promising novel biomarkers for diagnosis and prognosis of CVDs. Furthermore, emerging evidence uncovered miRNAs as new targets and/or regulators of cardiovascular medications given the ability of miRNAs to interact with some cardiovascular drugs, which opens up new opportunities for the research and development of novel CVD drugs. Herein, we summarize current knowledge regarding the potential applications of miRNAs in the therapy of CVD, including myocardial ischemia, cardiac hypertrophy/heart failure, interstitial fibrosis, arrhythmia, diabetes and hypertension and discuss the therapeutic potential and challenge of miRNAs in drug discovery.
Keywords: MicroRNA (miRNA), drug discovery, myocardial ischemia, cardiac hypertrophy, cardiac fibrosis, arrhythmias, heart failure, hypertension, diabetes, therapy, biomarker.
Current Drug Targets
Title:MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases
Volume: 18 Issue: 4
Author(s): Pengzhou Hang, Jing Guo, Chuan Sun and Zhimin Du
Affiliation:
Keywords: MicroRNA (miRNA), drug discovery, myocardial ischemia, cardiac hypertrophy, cardiac fibrosis, arrhythmias, heart failure, hypertension, diabetes, therapy, biomarker.
Abstract: MicroRNAs (miRNAs) are small conserved noncoding RNAs which function as posttranscriptional regulators of gene expression. Studies over the last 20 years have revealed the essential functions of miRNAs in regulating cardiovascular biology (such as cardiovascular cell differentiation, growth, proliferation and apoptosis) and crucial roles in controlling cardiovascular disease (CVD), indicating the potential of these small molecules as therapeutic targets and/or agents for CVD. Moreover, miRNAs in the circulation or other body fluids are stable and readily detectable, and more importantly often disease-associated, which makes them promising novel biomarkers for diagnosis and prognosis of CVDs. Furthermore, emerging evidence uncovered miRNAs as new targets and/or regulators of cardiovascular medications given the ability of miRNAs to interact with some cardiovascular drugs, which opens up new opportunities for the research and development of novel CVD drugs. Herein, we summarize current knowledge regarding the potential applications of miRNAs in the therapy of CVD, including myocardial ischemia, cardiac hypertrophy/heart failure, interstitial fibrosis, arrhythmia, diabetes and hypertension and discuss the therapeutic potential and challenge of miRNAs in drug discovery.
Export Options
About this article
Cite this article as:
Hang Pengzhou, Guo Jing, Sun Chuan and Du Zhimin, MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases, Current Drug Targets 2017; 18 (4) . https://dx.doi.org/10.2174/1389450117666160301101221
DOI https://dx.doi.org/10.2174/1389450117666160301101221 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interstitial Lung Disease in Systemic Lupus Erythematosus, Sjogren’s Syndrome, and Mixed Connective Tissue Disease
Current Respiratory Medicine Reviews Depression has a Strong Relationship to Alterations in the Immune, Endocrine and Neural System
Current Psychiatry Reviews Life and Death Partners in Post-PCI Restenosis: Apoptosis, Autophagy, and The Cross-talk Between Them
Current Drug Targets cGMP Signaling, Phosphodiesterases and Major Depressive Disorder
Current Neuropharmacology Surgical or Interventional Revascularization in Diabetic Patients with Coronary Artery Disease?
Current Diabetes Reviews Medial Vascular Calcification in Diabetes Mellitus and Chronic Kidney Disease: The Role of Inflammation
Cardiovascular & Hematological Disorders-Drug Targets PREPL, a Prolyl Endopeptidase-Like Enzyme by Name Only? – Lessons from Patients
CNS & Neurological Disorders - Drug Targets Lipoprotein (a) Levels and Abdominal Aortic Aneurysm. A Systematic Review and Meta-analysis
Current Pharmaceutical Design Hybrid Bioactive Heterocycles as Potential Antimicrobial Agents: A Review
Mini-Reviews in Medicinal Chemistry Arginine Deprivation as a Targeted Therapy for Cancer
Current Pharmaceutical Design Vascular Reactions of Iodinated X-Ray Contrast Media: Mechanisms and Possible Therapeutic Interventions
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Meet the Associate Editorial Board Member
Current Cardiology Reviews Role of Oxidative and Nitrosative Stress, Longevity Genes and Poly(ADPribose) Polymerase in Cardiovascular Dysfunction Associated with Aging
Current Vascular Pharmacology Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy The Concept of Phenoptosis and its Usefulness for Controlling Aging
Current Aging Science IP6 & Inositol in Cancer Prevention and Therapy
Current Cancer Therapy Reviews Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Optimizing the Management of Uncontrolled Hypertension: What do Triple Fixed-Dose Drug Combinations Add?
Current Vascular Pharmacology Prevalence and Co-prevalence of Comorbidities among Patients with Type 2 Diabetes Mellitus in the MENA Region: A Systematic Review
Current Diabetes Reviews